benzoxazoles has been researched along with sulpiride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jackson, MJ; Jenner, PG; Johnston, LC; Jones, CA; McCreary, AC; Rose, S; Smith, LA; van Scharrenburg, G | 1 |
| Kumei, S; Miyagishi, S; Nozu, T; Ohhira, M; Okumura, T; Takakusaki, K | 1 |
2 other study(ies) available for benzoxazoles and sulpiride
| Article | Year |
|---|---|
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Topics: Animals; Apomorphine; Benzoxazoles; Callithrix; Dopamine Agonists; Female; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Sulpiride | 2010 |
Levodopa acts centrally to induce an antinociceptive action against colonic distension through activation of D2 dopamine receptors and the orexinergic system in the brain in conscious rats.
Topics: Analgesics; Animals; Benzoxazoles; Brain; Consciousness; Injections, Intraventricular; Injections, Subcutaneous; Levodopa; Male; Naphthyridines; Orexin Receptor Antagonists; Orexin Receptors; Pain Threshold; Rats, Sprague-Dawley; Receptors, Dopamine D2; Sulpiride; Urea; Visceral Pain | 2016 |